Ohio Medicaid GLP-1 Coverage (2026): Triple-Anchored Weight-Loss Exclusion + the January 2026 Wegovy MACE/MASH Carve-Back-In

Ohio Medicaid — administered by the Ohio Department of Medicaid (ODM) with outpatient pharmacy processed through Gainwell Technologies, the state's Single Pharmacy Benefit Manager (SPBM) — is the most explicitly anchored non-coverage state in our 50-state Medicaid GLP-1 series so far. Ohio's weight-loss exclusion is triple-anchored by three independent primary-source layers: federal statute (42 U.S.C. § 1396r-8(d)(2)(A)), Ohio state regulation (Ohio Administrative Code 5160-9-03(B)(1) — “Drugs for the treatment of obesity” expressly non-covered), and a real-time SPBM claim-adjudication gate (Gainwell SPBM November 7, 2025 notice, effective December 8, 2025: “For all other non-FDA approved uses (such as prediabetes or weight loss), coverage will not be available”). The OAC also forecloses prior authorization as a route around the exclusion: paragraph (D) states that drugs in the non-covered list “are not eligible for prior authorization.”

The headline finding of the January 7, 2026 Ohio Medicaid Pharmacy & Therapeutics (P&T) Committee meeting is the opening of a new drug class — “Metabolic Modifiers: GLP-1 Agonists for Non-Obesity Indications” — that places Wegovy as Preferred, Clinical PA Required for the FDA-approved MACE (major adverse cardiovascular event reduction) and noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) indications. This carve-back-in is broader than California's April 2026 MASH-only Wegovy carve-back-in (which covers MASH only), but stricter than the FDA Wegovy MACE label on diabetes: Ohio explicitly excludes any patient with type 1 or type 2 diabetes from the Wegovy MACE pathway (A1C must be less than 6.5%). A patient with established cardiovascular disease AND type 2 diabetes meets the FDA Wegovy MACE label criteria — but does NOT meet Ohio's criteria. Wegovy for chronic weight management (no CVD, no MASH) remains not covered. Zepbound, Saxenda, and Foundayo are not on the Ohio UPDL under any indication.

What Ohio Medicaid covers (the bottom line)

Ohio Medicaid's GLP-1 coverage as of the January 7, 2026 P&T Committee meeting:

• T2D-indicated GLP-1s on the UPDL (Endocrine Agents: Diabetes — Non-Insulin): Preferred = Byetta (exenatide), Trulicity (dulaglutide), Victoza (liraglutide BvG — brand preferred over generic). Non-Preferred (PA required with T2D step therapy) = Bydureon BCise (extended-release exenatide), liraglutide generic, Mounjaro (tirzepatide), Ozempic (semaglutide), Rybelsus (oral semaglutide), Soliqua (insulin glargine + lixisenatide), Xultophy (insulin degludec + liraglutide). All require documented type 2 diabetes mellitus diagnosis; authorization period is 365 days.
• Wegovy (semaglutide) for MACE reduction (cardiovascular event prevention): Preferred, Clinical PA Required under the new Metabolic Modifiers — GLP-1 Agonists for Non-Obesity Indications class created January 7, 2026. Requires age ≥ 18, BMI ≥ 27 kg/m², documented prior MI / stroke / symptomatic PAD / ASCVD-related amputation, A1C < 6.5% (no type 1 or type 2 diabetes), and concurrent CVD standard-of-care medications. 180-day approval. Continuation requires ≥ 5% weight loss from baseline and 80% proportion of days covered (PDC).
• Wegovy (semaglutide) for noncirrhotic MASH (stage F2/F3 fibrosis): Preferred, Clinical PA Required under the same Metabolic Modifiers class. Requires age ≥ 18, biopsy-confirmed or imaging-confirmed F2/F3 fibrosis, lifestyle modifications, optimized care for concomitant CAD/dyslipidemia/hypertension, and no concurrent resmetirom or other GLP-1. 180-day approval.
• Wegovy for chronic weight management (no CVD, no MASH): NOT COVERED. Federal authority + OAC 5160-9-03(B)(1) + Nov 7, 2025 SPBM notice. No PA pathway available.
• Zepbound, Saxenda, Foundayo: NOT listed anywhere in the Ohio Medicaid UPDL or Metabolic Modifiers class under any indication. No PA pathway exists for these drugs under Ohio Medicaid.
• Imcivree (setmelanotide): status under Ohio Medicaid for members with confirmed POMC/PCSK1/LEPR deficiency or Bardet-Biedl syndrome is NOT VERIFIED in the primary sources reviewed for this article. We do not assert coverage or non-coverage without an additional Ohio-specific primary source.

The core clinical distinction: Ohio Medicaid has robust, well-defined T2D GLP-1 coverage and a newly created non-obesity Wegovy pathway for MACE and MASH — but zero weight-loss-indication GLP-1 coverage, and the PA route is explicitly foreclosed by administrative regulation.

The triple-anchored weight-loss exclusion

Three independent primary-source layers converge on Ohio's exclusion of GLP-1 weight-loss prescriptions. Each layer is verbatim- quoted from a verified primary-source document, and each operates independently — any one layer alone would be sufficient to establish non-coverage. Together they constitute the most explicitly anchored exclusion in our five-state series.

Anchor 1 — Federal authority: 42 U.S.C. § 1396r-8(d)(2)(A)

Federal Medicaid drug-coverage rules permit — but do not require — states to exclude certain enumerated categories of drugs from coverage. The relevant category, verbatim from 42 U.S.C. § 1396r-8(d)(2)(A) (Cornell LII, verified 2026-05-10):

“(2) List of drugs subject to restriction
The following drugs or classes of drugs, or their medical uses, may be excluded from coverage or otherwise restricted:
(A) Agents when used for anorexia, weight loss, or weight gain.”

This is a federal optional exclusion category — states may elect to use it, but they are not mandated to. Ohio has elected to use this authority and has codified the election in Ohio Administrative Code (Anchor 2) and operationalized it through the Gainwell SPBM claim gate (Anchor 3).

YMYL hedging boundary: we describe the federal authority as permissive, not mandatory. States that elect to cover GLP-1s for weight loss (the 13 states in KFF's January 2026 tracker) are also acting within federal law. We do NOT opine on the constitutional or administrative-law basis of any single anchor layer.

Anchor 2 — Ohio state regulation: OAC 5160-9-03(B)(1)

Ohio's exclusion is also anchored at the state-regulation level in Ohio Administrative Code Rule 5160-9-03 — “Pharmacy services: covered drugs and associated limitations” — effective February 16, 2024. Verbatim from paragraph (B):

“(B) Non-covered drugs
Drugs that fall into one of the following categories are non-covered by the Ohio medicaid pharmacy program:
(1) Drugs for the treatment of obesity.
(2) Drugs for the treatment of infertility.
(3) Drugs for the treatment of erectile dysfunction.
(4) Drug efficacy study implementation (DESI) drugs or drugs that are determined to be identical, similar, or related.
(5) Drugs that are covered or are eligible to be covered by medicare part D, when prescribed for a recipient who is eligible for medicare.”

And paragraph (D) of the same rule — the clause that forecloses PA as a workaround — verbatim:

“(D) Prior authorization
Dangerous drugs not listed in accordance with paragraph (C) of this rule that are medically necessary for treatment require prior authorization; however, noncovered drugs listed in paragraphs (B)(1) to (B)(5) of this rule and APIs and excipients not on the list described in paragraph (A)(3) of this rule are not eligible for prior authorization.”

Three critical implications:

1. The exclusion is at the Ohio Administrative Code level, not at the formulary level. Changing Ohio Medicaid's obesity-drug exclusion requires a formal Ohio 119.03 rulemaking process — not a PDL update or a P&T vote. This makes Ohio's exclusion more structurally durable than California's budget-bill reversal (which can be reversed biennially) or Texas's plan-level operational non-coverage (which rests on PBM contract terms).
2. Paragraph (D) forecloses the PA route. Under Ohio Medicaid, drugs on the (B)(1)–(B)(5) non-covered list “are not eligible for prior authorization.” A prescriber cannot file a PA for Wegovy, Zepbound, or Saxenda for the chronic- weight-management indication and expect Gainwell to review it on the merits. The claim will not be adjudicated as a coverage question — it is excluded as a class.
3. Ohio OAC 5160-9-03(B)(1) is structurally analogous to New York's 18 NYCRR § 505.3(g)(3). Both are state-regulation hooks that operate alongside (not instead of) the federal 42 U.S.C. § 1396r-8(d)(2)(A) authority. Ohio and New York are the only two states in our five-state series with this dual regulatory anchoring at both federal statute and state-regulation level.

Anchor 3 — Gainwell SPBM operational notice (November 7, 2025; effective December 8, 2025)

The third anchor is the operational real-time claim-adjudication gate. The Gainwell SPBM posted a notice on spbm.medicaid.ohio.gov dated November 7, 2025, effective December 8, 2025. Verbatim:

“11/07/2025
Effective 12.08.2025, claims for preferred GLP-1 receptor agonists (listed below), will require a diagnosis of ‘diabetes mellitus, type 2’ to be documented in the member’s medical record (as determined by medical claims data) or submitted on the pharmacy claim. For members with a diagnosis of ‘diabetes mellitus, type 2’ documented, claims will continue to be eligible for coverage under the Ohio Medicaid pharmacy benefit. For all other non-FDA approved uses (such as prediabetes or weight loss), coverage will not be available.

Preferred GLP-1 receptor agonists include:
• Byetta/exenatide
• Trulicity/dulaglutide
• Victoza/liraglutide”

This notice is the most operationally immediate of the three anchors. It establishes:

1. The type 2 diabetes diagnosis is required at claim adjudication, not just at PA review. As of December 8, 2025, Gainwell checks medical-claims history OR the ICD-10 code on the pharmacy claim before the claim passes.
2. The notice explicitly names “weight loss” as a non- covered indication, alongside “prediabetes.”
3. The notice names the three preferred GLP-1s by brand — Byetta/exenatide, Trulicity/dulaglutide, Victoza/liraglutide — confirming the brand-named scope. This distinguishes Ohio from Florida (which has no equivalent named operational notice) and aligns it with New York's NYRx contractor brand-name exclusion language.

Ohio is the only state in our five-state series with a real-time SPBM claim-edit gate in addition to the federal statute and state regulation. The New York NYRx contractor notice names brands in a provider-facing policy document; Ohio's Gainwell gate enforces the T2D diagnosis at point-of-sale adjudication — a tighter operational control.

The January 7, 2026 P&T carve-back-in: a new drug class for non-obesity Wegovy indications

The most significant recent development in Ohio Medicaid GLP-1 policy is the January 7, 2026 P&T Committee meeting, which did not change the weight-loss exclusion but did open a new PA-accessible pathway for Wegovy under two FDA-approved non-obesity indications. Verbatim from the January 7, 2026 P&T meeting minutes (section IX, “Drug Class Announcement”):

“a. Metabolic Modifiers
ODM proposed a new drug class, Metabolic Modifiers: GLP-1 Receptor Agonists for Non-Obesity Indications, with the placement of the medication as listed below. Dr. Capp provided a clinical overview of MACE and MASH along with the use of Wegovy for these two indications. ODM provided an overview of the clinical criteria and recommended Wegovy as ‘Preferred, Clinical PA Required’. The Committee suggested naming the drug category Metabolic Modifiers and having a sub-category for GLP-1 Agonists for Non-Obesity Indications. After some discussion, the Committee voted and recommended the category and clinical criteria as shown below:”

The new class approved by the Committee:

The class title itself — “GLP-1 Agonists for Non-Obesity Indications” — is the Committee's chosen language and signals the intended scope: this is not weight-management coverage, and the class name forecloses any interpretation that it represents a rollback of the OAC 5160-9-03(B)(1) obesity-drug exclusion. The carve-back-in exists because Wegovy has two FDA-approved indications that are mechanistically distinct from chronic weight management: MACE reduction in patients with established cardiovascular disease (FDA March 8, 2024), and treatment of noncirrhotic MASH (FDA August 15, 2025). Ohio is covering Wegovy for those non-obesity indications, not for weight loss.

Important framing for patients and prescribers: the UPDL is a living document. The January 7, 2026 P&T-approved updates supersede any conflicting earlier listings. The actual published UPDL on spbm.medicaid.ohio.gov may carry an effective date that lags the P&T meeting date. Always verify the current UPDL publication before submitting a PA for Wegovy under the Metabolic Modifiers class.

The Wegovy MACE pathway: BMI ≥ 27, but no diabetes (stricter-than-label T2D exclusion)

Ohio's Wegovy MACE PA criteria contain one of the most clinically unusual utilization controls in our five-state series. The BMI threshold is lower than New York's (Ohio uses BMI ≥ 27 kg/m², matching the FDA label; NY requires BMI ≥ 40) — but Ohio explicitly excludes patients with type 1 or type 2 diabetes, which the FDA Wegovy MACE label does NOT do. Verbatim from the January 7, 2026 P&T meeting minutes, Metabolic Modifiers section:

“CLINICAL PA CRITERIA:
• Initial review for diagnosis of Major Adverse Cardiovascular Events (MACE)
  o Age ≥18 years
  o BMI ≥27 kg/m²
  o The prescriber must attest that the requested medication will not be received in combination with any other GLP-1, GLP-1/GIP
  o Documentation (chart notes) must be submitted to show that the patient has history of one of the following and provides documentation (chart notes):
    • Prior Myocardial Infarction
    • Prior stroke
    • Symptomatic peripheral artery disease (PAD) as evidenced by one or more of the following:
      • Intermittent claudication with an ankle-brachial index (ABI) less than 0.85 (at rest)
      • Peripheral arterial revascularization procedure (e.g., endarterectomy, angioplasty, stenting)
      • Amputation due to Atherosclerotic Cardiovascular Disease (ASCVD)
  o Documentation (chart notes) must be submitted to show the patient does not have type 1 or 2 diabetes. The A1C must be less than 6.5%. Wegovy will not be authorized for patients with type 1 or type 2 diabetes. (For patients with type 1 or 2 diabetes, please see the Endocrine Agents: Non-insulin Agents category)
  o The patient is receiving standard of care for the treatment of cardiovascular disease (CVD), as appropriate/indicated, including an antiplatelet agent (aspirin or platelet aggregation inhibitor), lipid-lowering drug (statin, ezetimibe, fibrate, and/or PCSK-9 inhibitor), and an antihypertensive (beta blocker, ACEI, ARB). Documentation (chart notes) must be submitted to support current medication use or contraindications to these treatments (as applicable)”

And the continuation criteria for MACE, verbatim:

“SUBSEQUENT AUTHORIZATION CRITERIA:
• Major Adverse Cardiovascular Events (MACE)
  o The prescriber attests that the patient is being monitored for efficacy and safety
  o Documentation (chart notes) must be submitted to show weight loss from baseline greater than or equal to 5%
  o Adherence documented by claims supporting an 80% proportion of days covered
  o Documentation (chart notes) must be submitted to show the patient does not have type 1 or 2 diabetes. The A1C must be less than 6.5%. Wegovy will not be authorized for patients with type 1 or type 2 diabetes. (For patients with type 1 or 2 diabetes, please see the Endocrine Agents: Non-insulin Agents category)”

Four critical clinical-framing points:

1. The BMI ≥ 27 threshold matches the FDA Wegovy MACE label. Ohio does NOT impose the elevated BMI ≥ 40 threshold that New York's NYRx uses. Any adult age ≥ 18 with BMI ≥ 27 and documented prior MI / stroke / symptomatic PAD meets the BMI component.
2. The diabetes exclusion (A1C < 6.5%, no T1D or T2D) is stricter than the FDA Wegovy MACE label. The FDA MACE label permits Wegovy for adults with established cardiovascular disease regardless of diabetes status — T2D is explicitly permitted in the clinical trial population. Ohio routes patients with T2D who have CVD to the GLP-1 T2D class (Endocrine Agents: Diabetes — Non-Insulin), not the Metabolic Modifiers class. A patient with both established CVD and T2D meets the FDA MACE criteria for Wegovy but does NOT meet Ohio's Metabolic Modifiers PA criteria. This is a state-level utilization restriction, not an FDA-label restatement. Prescribers must be aware of this divergence.
3. The CVD documentation requirement is specific about qualifying events. The MACE pathway requires prior MI, prior stroke, symptomatic PAD with ABI < 0.85 / revascularization / ASCVD amputation. General cardiovascular risk factors — hypertension, dyslipidemia, family history — do NOT qualify. A patient with hypertension and obesity but no prior cardiac event does not meet the criteria, regardless of BMI.
4. No lifetime treatment-attempt limit. Unlike New York's NYRx pathway (which caps at two lifetime Wegovy treatment attempts), the Ohio January 7, 2026 PA criteria contain no documented lifetime cap. Patients who discontinue and restart may be eligible for reauthorization if they re-meet the initial criteria. Verify the current published UPDL — this may change in a future P&T cycle.

The Wegovy MASH pathway: noncirrhotic F2/F3 fibrosis (stage-specific)

Ohio's January 7, 2026 Wegovy MASH PA criteria are distinct from the MACE pathway and do not carry the T2D exclusion. Verbatim from the January 7, 2026 P&T meeting minutes:

“• Initial review for diagnosis of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
  o Age ≥18 years
  o Must have documented noncirrhotic MASH with moderate to advanced liver fibrosis (stage F2 or F3) confirmed by liver biopsy within the prior 24 months OR
  o Must have documented noncirrhotic MASH and moderate to advanced liver fibrosis (stage F2 or F3) confirmed by TWO of the following:
    • Fibrosis-4 index greater than 1.3, magnetic resonance elastography (MRE), MRI aspartate aminotransferase (MAST), liver stiffness measurement (LSM) by vibration controlled transient elastography (e.g., Fibroscan)
  o Must attest that the patient has received instruction on a reduced calorie diet and increased physical activity and is adherent to these lifestyle modifications
  o Must attest that the patient has optimized care for concomitant related conditions, including coronary artery disease, dyslipidemia, hypertension
  o Not currently on another treatment for MASH (e.g., resmetirom)
  o Not currently on another GLP-1 Receptor Agonist containing agent”

Continuation criteria for MASH, verbatim:

“• Metabolic Dysfunction-Associated Steatohepatitis (MASH)
  o Weight loss from baseline of 5% or greater
  o Has the patient experienced a positive clinical response from Wegovy as defined by the following:
    • Resolution of steatohepatitis and no worsening of liver fibrosis, OR
    • At least one stage improvement in liver fibrosis and no worsening of steatohepatitis
  o Must have been adherent with using Wegovy, with claims supporting an 80% proportion of days covered”

Clinical scope and limitations:

• F2/F3 fibrosis only. Patients with mild fibrosis (stage F0 or F1) or compensated cirrhosis (stage F4) do not qualify. The FDA Wegovy MASH label (approved August 15, 2025) covers noncirrhotic MASH with F2/F3 fibrosis — Ohio's criteria track the FDA label exactly on this point.
• No T2D exclusion applies to the MASH pathway. Unlike the MACE pathway, the MASH criteria do not contain a diabetes exclusion. A patient with T2D and confirmed F2/F3 noncirrhotic MASH may apply under this pathway if not currently on another GLP-1 T2D agent.
• Ohio's MASH pathway is broader than California's. California Medi-Cal Rx added Wegovy back to the CDL effective April 1, 2026 for MASH only. Ohio created both the MASH and MACE pathways simultaneously in January 2026. Both states converged on non-obesity Wegovy coverage around the same time, but Ohio's scope is wider.
• Continuation requires clinical response at 180 days. Patients not achieving ≥ 5% weight loss or the specified histologic/imaging improvement criteria will not be reauthorized. The 180-day initial authorization window means the first renewal review comes six months after initiation.

The GLP-1 T2D class: PDL listings and PA criteria

The January 7, 2026 P&T Committee confirmed the following GLP-1 listings for the type 2 diabetes class (“Endocrine Agents: Diabetes — Non-Insulin: GLP-1 RECEPTOR AGONISTS/COMBINATIONS”):

“BvG” = Brand preferred over the generic equivalent. Victoza (brand liraglutide T2D 1.8 mg) is Preferred; liraglutide generic is Non-Preferred. These are the T2D-indication listings only; they are entirely separate from the Metabolic Modifiers class Wegovy listing.

T2D GLP-1 class PA criteria (verbatim)

For Non-Preferred agents, the January 7, 2026 P&T-approved Non-Preferred criteria, verbatim:

“LENGTH OF AUTHORIZATIONS: 365 Days

NON-PREFERRED CRITERIA:
• Must have had an inadequate clinical response of at least 120 days with at least three preferred drugs in this UPDL category and indicated for diagnosis, if available
  o Must include a patient specific A1C goal if less than 7%
  o Must include current A1C (within last 6 months)
  o Two preferred drugs must be used concurrently and one of the drugs must be in the same sub-section as the requested medication
  o Three preferred drugs must be titrated to maximum treatment dose (must achieve maximum recommended dose for 120 days or document that maximum recommended dose is not tolerated or is clinically inappropriate)”

Additional Mounjaro (tirzepatide) criteria, verbatim:

“ADDITIONAL TIRZEPATIDE (MOUNJARO) CRITERIA
• Prior to initiation, must have hemoglobin A1C >7% AND
• Must have had an inadequate clinical response of at least 120 days with OZEMPIC OR must provide documentation of medical necessity for patient’s inability to use OZEMPIC”

The subsequent authorization criteria require an A1C within the last 6 months and must demonstrate improvement from baseline:

“SUBSEQUENT AUTHORIZATION CRITERIA:
• Must provide documentation of patient’s clinical response to treatment and ongoing safety monitoring
  o Must submit recent hemoglobin A1C level (within 6 months)
  o Must include documentation showing improvement in current A1C (within last 6 months) if not already at goal A1C
  o Must include current A1C
    • Must be from within last 6 months
    • Must demonstrate improvement from baseline when the requested medication was initiated”

For patients with T2D, the overall T2D GLP-1 coverage is robust: both T2D semaglutide (Ozempic) and T2D tirzepatide (Mounjaro) are Non-Preferred with well-defined PA pathways. The step-therapy requirement for Mounjaro (120-day Ozempic trial or documented intolerance) is the most demanding in the class, including a specific GI-tolerance protocol.

The Gainwell SPBM: why plan-level divergence is structurally impossible

Ohio launched its Single Pharmacy Benefit Manager (SPBM) model with Gainwell Technologies on October 1, 2022, consolidating outpatient pharmacy for all Medicaid managed-care plans into a single statewide PBM. Ohio then extended Gainwell to fee-for-service (FFS) effective July 1, 2023. Verbatim from the Gainwell SPBM October 1, 2022 launch notice:

“Gainwell Technologies and the Ohio Department of Medicaid (ODM) launched the Single Pharmacy Benefit Manager (SPBM) on October 1! Gainwell has already contracted with more than 2600 pharmacies. ODM’s goals for the SPBM are to improve management and administration of pharmacy benefits for Ohio Medicaid managed care members. Through the SPBM, ODM gains increased accountability and ensures alignment with clinical and policy goals, while also improving transparency.”

And the July 1, 2023 FFS extension notice, verbatim:

“Beginning on July 1, 2023, in addition to Ohio Medicaid Managed Care, Gainwell Technologies will be the Single Pharmacy Benefit Manager (SPBM) for Ohio Medicaid Fee for Service. ODM’s continued goal for the SPBM are to improve management and administration of pharmacy benefits for Ohio Medicaid members. Through the SPBM, ODM gains increased accountability and ensures alignment with clinical and policy goals, while also improving transparency.”

The practical consequence: every Ohio Medicaid beneficiary — whether enrolled in FFS or in any of the contracted managed-care plans (CareSource, Buckeye Health Plan, AmeriHealth Caritas Ohio, Molina Healthcare of Ohio, Anthem BCBS Ohio, Humana Healthy Horizons OH) — receives their outpatient pharmacy benefit through Gainwell Technologies under the Unified Preferred Drug List (UPDL). Plan-level GLP-1 PA divergence is structurally impossible under this model. A patient enrolled in CareSource does not get different GLP-1 coverage than a patient enrolled in Buckeye or in FFS.

This model is structurally analogous to New York's NYRx program (Prime Therapeutics) and California's Medi-Cal Rx (Magellan Medicaid Administration). It collapses the FFS-vs-MCO complexity that drives variation in states like Florida (where SMMC plans retain discretion on some drug-class policies) and Texas (where STAR+PLUS plans have limited plan-level discretion on non-preferred agents).

Verified MCO deferrals to the Gainwell SPBM

Three Ohio Medicaid managed-care plans have published verbatim deferral language confirmed by direct HTTP 200 fetch on 2026-05-10:

• Buckeye Health Plan (Centene): “ODM selected Gainwell Technologies as the SPBM for Ohio Medicaid” + “On October 1, 2022, the SPBM will begin providing pharmacy services across all managed care plans and members” + “Through the Unified Preferred Drug List (UPDL), Buckeye Health Plan covers certain prescription drugs and over-the-counter drugs when prescribed by a Buckeye Health Plan provider.”
• AmeriHealth Caritas Ohio: “AmeriHealth Caritas Ohio members will use Gainwell to process prescription claims” — and notably, AmeriHealth Caritas Ohio publishes the OAC 5160-9-03(B) excluded-drug list verbatim on its pharmacy page, leading with “Drugs for treatment of obesity” as the first non-covered category.
• CareSource Ohio Medicaid: “Gainwell Technologies is the Single Pharmacy Benefit Manager (SPBM) for the Ohio Department of Medicaid (ODM) pharmacy program. All CareSource members receive pharmacy benefits through the SPBM.” + “Gainwell Technologies uses the Unified Preferred Drug List (UPDL), which is a list of drugs covered under the plan.”

Important hedge: Molina Healthcare of Ohio returned a bot-block error in our verification session and is not individually verified. Anthem BCBS Ohio and Humana Healthy Horizons OH are also not individually verified in this brief. All contracted Ohio MCOs are bound by the SPBM statutory mandate; the three verified deferral statements above are representative of the structural reality. We do NOT assert individual plan-level PA criteria that diverge from the UPDL without a verified plan-specific primary source.

Excluded populations and populations with separate rules

Under the Ohio Medicaid SPBM-administered UPDL:

• Adults with obesity (BMI ≥ 30) without T2D — excluded for GLP-1 weight-loss coverage. No PA pathway available. OAC 5160-9-03(D) forecloses even filing a PA.
• Adults with overweight (BMI 27–29.9) plus weight-related comorbidities, without T2D and without established CVD events — excluded for weight-loss GLP-1 coverage. Patients with BMI ≥ 27 and documented prior MI / stroke / symptomatic PAD may qualify for Wegovy under the Metabolic Modifiers MACE pathway if A1C is < 6.5% and no T1D/T2D.
• Adults with T2D AND obesity — NOT restricted for the T2D GLP-1 indication (subject to PA criteria). The GLP-1 must be adjudicated against the T2D diagnosis, not the obesity diagnosis. The November 7, 2025 SPBM notice makes this explicit. These patients cannot access the Metabolic Modifiers Wegovy class.
• Adults with prediabetes and obesity — excluded. The November 7, 2025 SPBM notice names “prediabetes” as a non-covered GLP-1 indication alongside weight loss.
• Adolescents and pediatric members (under age 18) — excluded from the Metabolic Modifiers MACE and MASH pathways (age ≥ 18 requirement). Weight-loss GLP-1 coverage is excluded under OAC 5160-9-03(B)(1) regardless of age.
• MyCare Ohio dual-eligibles — Ohio operates a dual-eligible Medicare-Medicaid alignment program called MyCare Ohio in 29 demonstration counties. Per OAC 5160-9-03(B)(5), drugs covered or eligible for coverage by Medicare Part D when prescribed for a Medicare-eligible recipient are non-covered by the Ohio Medicaid pharmacy program. For Medicare-eligible Ohio Medicaid members, coverage of GLP-1s is governed by the member's Medicare Part D plan, not Ohio Medicaid. MyCare Ohio dual-eligibles have separate coverage rules that are NOT fully verified in the primary sources reviewed for this article. MyCare Ohio members should verify GLP-1 coverage with their Medicare Part D plan and their MyCare Ohio plan coordinator.
• Compounded GLP-1s — semaglutide and tirzepatide are not listed in any verified Ohio Medicaid compounding-eligible API materials. The FDA drug-shortage status for semaglutide ended October 2024 and tirzepatide ended December 2024; compounded versions of either are generally not appropriate under FDA section 503A/503B rules following shortage resolution. Compounded GLP-1s are not a viable Ohio Medicaid coverage pathway.

HB 388: the state employee GLP-1 reimbursement bill (NOT Medicaid)

Ohio HB 388 in the 136th General Assembly has attracted attention as a potential sign of legislative momentum on GLP-1 access in Ohio. Verbatim bill title and scope from legislature.ohio.gov(verified 2026-05-10):

“House Bill 388
Regards state employee reimbursement for GLP-1 drug costs
To enact section 124.826 of the Revised Code regarding reimbursements to state employees and elected state officials for GLP-1 drug costs.”

Current bill status, verbatim:

“Current Version: As Introduced
Introduced In House: &check;
In House Committee: &check; House General Government Committee
Reported By Committee: (not yet)
Passed By House: (not yet)
Introduced In Senate: (not yet)”

Primary sponsors: Josh Williams; Dontavius L. Jarrells.

CRITICAL FRAMING: HB 388 is a state-employee benefits bill, NOT a Medicaid bill. HB 388 enacts Ohio Revised Code section 124.826 to require the Ohio Department of Administrative Services (DAS) to reimburse state employees and elected officials up to $500/month in the first year and $250/month in the second year for GLP-1 drug costs purchased through a manufacturer direct-to-consumer program or participating pharmacy. It is a direct response to DAS's elimination of GLP-1 weight-loss coverage from the state employee health plan effective July 1, 2025. HB 388 does NOT reach the Ohio Medicaid pharmacy program, does NOT modify OAC 5160-9-03(B)(1), and does NOT modify the ODM Gainwell UPDL. Even if enacted exactly as introduced, it would have zero effect on Ohio Medicaid GLP-1 weight-loss coverage. We do not predict legislative outcomes — HB 388 is introduced and pending in the House General Government Committee as of this writing and has not been reported by committee.

KFF classification: Ohio is not among the 13 states covering GLP-1s for obesity

KFF's January 16, 2026 “Medicaid Coverage of and Spending on GLP-1s” tracker states:

“Obesity drug coverage in Medicaid remains limited, with 13 state Medicaid programs covering GLP-1s for obesity treatment under fee-for-service (FFS) as of January 2026.”

The 13 states (verified by direct source): Arkansas, Colorado, Connecticut, Delaware, Illinois, Louisiana, Massachusetts, Minnesota, New Mexico, New York, Oregon, Virginia, and Washington. Ohio is not in this list.

An important temporal note: the KFF tracker's January 16, 2026 cutoff date is nine days after the January 7, 2026 Ohio P&T Committee meeting that created the Metabolic Modifiers class. It is possible KFF's methodology (which appears to track chronic-weight-management coverage, not non-obesity-indication pathways) would still not classify Ohio as a “covering state” even with knowledge of the January 7, 2026 Wegovy Metabolic Modifiers class, because that class is explicitly labeled for non-obesity indications. We note this temporal ambiguity without predicting how KFF would update its classification in a subsequent tracker release.

Five-state taxonomy: where Ohio fits

Across our 50-state Medicaid GLP-1 coverage series, five states now have verified primary-source documentation:

Ohio's structural distinctions from each state in the series:

• Vs Texas: Ohio has a more explicit and more durable exclusion. Texas relies on plan-level press releases plus federal authority. Ohio anchors at three tiers. Texas's Acentra- administered PDL omits Wegovy/Zepbound/Saxenda without naming them as excluded; Ohio's SPBM notice explicitly names “weight loss” as non-covered at the claim-gate level.
• Vs California: Ohio's exclusion is at the Administrative Code level (OAC 5160-9-03) and requires rulemaking to reverse, making it more durable than California's budget-bill exclusion (reversible biennially). Both states added a Wegovy non-obesity carve-back-in around the same time — Ohio in January 2026 (MACE + MASH), California in April 2026 (MASH only). Ohio's carve-back-in is broader in scope.
• Vs New York: Ohio is the closest structural twin. Both are triple-anchored. Key differences: Ohio MACE BMI threshold = 27 (NY = 40, NY is stricter); Ohio MACE diabetes exclusion is explicit (NY does not formally exclude T2D from its MACE pathway); Ohio has a MASH pathway (NY does not, as of the April 23, 2026 NYRx PDL); Ohio has no lifetime treatment-attempt limit (NY caps at 2); Ohio uses a real-time claim-adjudication gate (NY uses a provider-facing policy document).
• Vs Florida: Florida's exclusion is silent (operational by absence, no named non-coverage notice); Ohio's is loud and triply named. Both states have no verified Medicaid legislative bill targeting weight-loss GLP-1 expansion in a meaningful committee stage. Ohio's SPBM structure eliminates plan-level variation; Florida's SMMC system allows minor plan-level discretion.

Appeal pathway: Ohio State Hearing process

Ohio Medicaid members who receive an adverse action on a GLP-1 PA may request a State Hearing through the Ohio Medicaid system. The appeal rules are at Ohio Administrative Code Rule 5101:6-3-02, effective April 1, 2023. Verbatim on the filing window:

“The individual shall be allowed ninety calendar days to request a hearing on any action or inaction.” (General programs — the 90-day period begins “on the day after the date the notice of action is mailed.”)

“The individual shall have ninety calendar days from the mail date of the MCP or MCOP appeal resolution decision to request a state hearing.” (Managed-care plans)

A hearing request may be made “orally, in writing, or electronically” per the rule.

Critical distinction: adjudication-error appeal vs policy-level denial. The state hearing process is designed to review whether the agency correctly applied policy, not whether the policy itself is correct. The hearing officer cannot overturn an OAC rule. This creates two fundamentally different appeal scenarios:

• Wegovy MACE/MASH PA denials (adjudication-error appeals): A state hearing can be appropriate and potentially successful here. If Gainwell denied the PA because documentation was missing or misapplied — for example, BMI documentation was in the chart but not submitted on the PA form, A1C documentation was present but Gainwell applied an incorrect threshold, or the fibrosis staging was from an MRI report that qualified under the dual-imaging-biomarker pathway but the reviewer missed it — the hearing officer can review the documentation and reverse the denial. Members should: (1) request the written denial with the specific PA criterion cited, (2) obtain chart documentation directly addressing each unmet criterion, (3) have the prescriber prepare a supplemental Letter of Medical Necessity, and (4) file within 90 days of the denial notice mail date.
• Wegovy / Zepbound / Saxenda for weight-loss indication (policy-level denials): A state hearing is generally not an effective route. Because OAC 5160-9-03(D) explicitly states that drugs on the non-covered list “are not eligible for prior authorization,” a weight-loss-indication denial is a coverage exclusion, not a PA- criteria adjudication. The hearing officer cannot override the Administrative Code. The realistic path to changing Ohio Medicaid GLP-1 weight-loss coverage runs through OAC 5160-9-03 rulemaking (Ohio's 119.03 process) or a General Assembly statutory change — not individual state hearings. We do NOT promise that any hearing or appeal will succeed, and we do NOT predict legislative or rulemaking outcomes.

Patient action steps

For Ohio Medicaid members seeking GLP-1 access:

1. Confirm your diagnosis category first. If you have a documented type 2 diabetes mellitus diagnosis (ICD-10 E11.x), your GLP-1 access question is about the T2D class PA pathway (Byetta/Trulicity/Victoza as Preferred; Ozempic/Mounjaro/Rybelsus as Non-Preferred with step therapy). This is a separate and distinct question from weight-loss coverage.
2. If you have established CVD (prior MI, stroke, symptomatic PAD, or ASCVD amputation) AND an A1C below 6.5% AND no diabetes diagnosis: discuss the Wegovy Metabolic Modifiers MACE pathway with your prescriber. The PA form requires documented chart notes for each qualifying cardiovascular event and documentation of current CVD standard-of-care medications (antiplatelet + lipid-lowering + antihypertensive). The 180-day approval requires ≥ 5% weight loss from baseline for continuation.
3. If you have confirmed noncirrhotic MASH with F2/F3 fibrosis: discuss the Wegovy Metabolic Modifiers MASH pathway with your hepatologist. You will need either a liver biopsy from the past 24 months or documentation of F2/F3 by two imaging biomarkers (FIB-4 > 1.3, MRE, MAST, Fibroscan LSM).
4. If you have obesity without T2D, established CVD, or confirmed MASH: there is no Ohio Medicaid PA pathway available for GLP-1 weight-management medications. The OAC 5160-9-03(D) explicitly forecloses PA. Discuss cash-pay options (NovoCare Wegovy $299/mo, LillyDirect Zepbound vials from $299/mo, Foundayo oral orforglipron $149/mo) or manufacturer patient-assistance programs with your prescriber.
5. Contact Gainwell with PA questions. The Gainwell SPBM contact for member and pharmacy PA inquiries is 1-833-491-0344. Verify the current UPDL status at spbm.medicaid.ohio.gov before submitting any PA. UPDL listings are subject to revision at each P&T Committee cycle.
6. PA denial at 180-day renewal for MACE/MASH: If continuation is denied for not meeting the ≥ 5% weight-loss criterion or the MASH histologic-response criterion, you have 90 days from the denial mail date to request a State Hearing. Adjudication-error appeals (missed documentation, wrong threshold applied) are more likely to succeed than policy-level appeals.

Related research in this series

• Pennsylvania Medicaid GLP-1 coverage 2026: the policy reversal — the closest structural twin for the MACE and MASH carve-out architecture. Both states cover Wegovy for MACE (BMI ≥ 27) and noncirrhotic MASH (F2/F3 fibrosis). Three key PA vs OH differences: PA's MACE pathway does NOT exclude T2D patients (Ohio explicitly excludes T1D/T2D, requiring A1C < 6.5%); PA's MASH biomarker panel is broader (ELF score accepted; age-stratified FIB-4 ≥ 1.3 / ≥ 2.0 thresholds; Ohio doesn't reference ELF); PA adds a Zepbound OSA pathway (Ohio has no OSA pathway as of January 2026). PA is also the policy-reversal counterpart: Ohio opened MACE/MASH carve-outs in January 2026 while Pennsylvania terminated its prior obesity-coverage pathway in the same month.
• New York Medicaid (NYRx) GLP-1 coverage and Wegovy MACE pathway (2026) — Ohio's closest structural twin in the five-state series. Both states have triple-anchored exclusions (federal + state regulation + state-PBM operational notice). Key comparisons: NY MACE BMI threshold = 40 (Ohio = 27); NY has no formal T2D exclusion from MACE (Ohio does, A1C < 6.5%); NY caps at 2 lifetime Wegovy attempts (Ohio has no cap); NY has no MASH pathway (Ohio does as of Jan 7, 2026).
• California Medi-Cal GLP-1 coverage (2026): the state reversal that removed Wegovy + Zepbound for weight loss — direct comparison for the non-obesity carve-back-in timeline. California added Wegovy back for MASH only (April 1, 2026, ICD-10 K76.0/K75.8). Ohio added Wegovy for both MACE and MASH simultaneously (January 7, 2026). Ohio's carve-back-in is broader in scope; California's exclusion is at the budget-bill level (more reversible); Ohio's is at the OAC-regulation level (more durable).
• Texas Medicaid GLP-1 coverage + STAR+PLUS PA pathway (2026) — the first article in the 50-state series. Texas has plan-level discretion through STAR+PLUS managed-care (Aetna, Molina, Superior HealthPlan, UnitedHealthcare Community Plan) operating under the state VDP PDL; Ohio's Gainwell SPBM consolidates all Medicaid pharmacy into one statewide PBM. Both states use the 42 USC § 1396r-8(d)(2)(A) federal authority; Ohio adds the OAC state-regulation anchor and the SPBM claim gate that Texas lacks.
• Florida Medicaid GLP-1 coverage (2026): the silent exclusion — the structural contrast to Ohio. Florida's exclusion is “operational by absence” with no named non-coverage notice; Ohio's is explicitly triply named. Ohio has a verified Wegovy non-obesity PA pathway (MACE + MASH); Florida does not. The Gainwell SPBM (Ohio) vs SMMC plan-level discretion (Florida) is the structural model contrast.
• GLP-1 insurance dropped coverage appeal playbook — the four-phase appeal logic; the Ohio-specific layer is the OAC 5101:6-3-02 State Hearing process (90-day filing window) with the adjudication-error vs policy-level appeal framing above.
• GLP-1 insurance coverage across Medicare, Medicaid, and commercial — the federal-state coverage framework and how the Ohio SPBM model interacts with the Medicare Part D Wegovy cardiovascular bridge for dual-eligibles.
• Wegovy alternatives 2026 — for Ohio Medicaid members who do not qualify for the Metabolic Modifiers MACE/MASH pathway and are evaluating Zepbound, Foundayo, Saxenda, and the cash-pay landscape.
• GLP-1 prior-authorization letter generator — embeds the verbatim Ohio Metabolic Modifiers MACE and MASH PA criteria into a Letter of Medical Necessity template usable for Gainwell SPBM submissions and State Hearing requests.
• Michigan Medicaid GLP-1 coverage (2026): Pattern #10 — partial retainment with morbid-obesity gate + bariatric-surgery-avoidance prescriber attestation — The most useful state-to-state comparison for Ohio’s non-obesity indication pathways. Both states have MACE and MASH carve-back-ins for Wegovy effective January 2026. Key divergences: Ohio’s MACE pathway explicitly excludes T1D/T2D (A1C < 6.5%); Michigan does not. Ohio has no chronic-weight-management pathway at any BMI; Michigan retains one at BMI ≥ 40 with the uniquely Michigan bariatric-surgery-avoidance attestation. Ohio’s authority is triply-anchored in OAC 5160-9-03(B)(1), Gainwell SPBM operational notice, and federal statute; Michigan’s restriction is driven entirely by an appropriations statute (Public Act 22 of 2025) and is structurally more reversible via the appropriations cycle.